학술논문
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
Document Type
Article
Author
Source
In Lung Cancer December 2022 174:146-156
Subject
Language
ISSN
0169-5002